AlphAIAlphAI — Financial news for AI agents
investing.comSEP 232 min read$CLDX

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

Guggenheim's biotech rankings place Celldex Therapeutics (CLDX) at the top due to positive Phase III trial results for barzovolimab in treating chronic spontaneous urticaria. The drug showed strong efficacy and a low rate of severe anaphylaxis. CLDX recently discontinued a prurigo nodularis study after it failed to meet endpoints. Analysts have mixed price target adjustments.

Original reporting
investing.com
Published Sep 23, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CLDX
Bullish
high confidence
Mentioned
$CLDX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CLDXBullishMed
01

Why it matters

The trial data provides fresh, material information that could shift CLDX valuation.

02

Market read

Positive Phase III results are a catalyst for CLDX and may influence biotech sentiment.

03

What to watch

Potential competition and reimbursement uncertainty could temper gains.

Relevance 8/10Novelty 9/10Timing: today

Background

Guggenheim's biotech rankings highlight top performers; CLDX leads after trial readout.

Company-level read

Ticker impact

$CLDXBullishHigh confidence
Context

Celldex Therapeutics reported highly positive topline Phase III results for barzovolimab in chronic spontaneous urticaria.

Expected impact

Potential short-term upside as investors price in efficacy data.

Evidence & confidence

Phase III success is material for a biotech and often triggers price moves.

Market effects

Sector

Biotech sector may see broader rally on positive urticaria data.

Regional

U.S. biotech investors likely to react.

Global

Limited to markets tracking biotech pipelines.

Counterpoint

What could challenge this read

Skeptics may question durability of response and safety profile.

Key entities

  • company
    Celldex Therapeutics

    Biotech firm developing barzovolimab.

  • analyst
    Guggenheim

    Investment firm publishing biotechnology rankings.

Read at source← All news

Related articles

SEP 23
$CLDXHighAI 9/10

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, meeting all primary and secondary endpoints. The drug showed significant efficacy, with a majority of patients achieving complete symptom relief. However, the company faces high R&D costs and a 2027 expected BLA filing. CLDX has $717.6M in cash and a pipeline of other studies, but a recent Phase 2 failure in prurigo nodularis highlights risks.

insidermonkey.com3 min
SEP 22
$CLDXHighAI 8/10

Why is Celldex Therapeutics stock sliding today?

Celldex Therapeutics (CLDX) stock fell 10.4% after Phase 3 trial results for barzolvolimab met primary and secondary endpoints but showed smaller efficacy gains than Phase 2. Analysts maintained positive ratings and price targets. The broader market had minimal impact, highlighting the company-specific move.

investing.com2 min
SEP 22
$CLDXMedAI 9/10

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.

stocktwits.com2 min
SEP 22
$CLDXMedAI 8/10

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria (CSU). Both studies met primary and secondary endpoints, showing significant symptom improvement. The treatment also showed sustained efficacy and a favorable safety profile. CLDX plans to submit a Biologics License Application to the FDA in 2027. Shares initially rose but later fell 12.51% to $36.65.

benzinga.com2 min